Goodwin, G.M., Aaronson, S.T., Alvarez, O., Arden, P.C., Baker, A., Bennett, J.C., Bird, C., Blom, R.E., Brennan, C., Bruber, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B.W., Eich, K., Feifel, D., Goldberg, M., Grinspoon, D., Hellerstein, D.J., Hoppe, A.G., Husain, M., Joshi, R.A., Kaber, S., Kelmendi, B., Kozlu, M., Leckman, J.F., Liebers, D., Liff, G.M., Mantz, D., Marton, S., McManus, E., Mithoefer, M., Muthukumaraswamy, S.D., Olson, D., Page, A., Papakostas, G.I., Posner, J., Riva-Posse, P., Roth, B.L., Rothberg, R.L., Short, B., Stade, E.C., Thomas, N., Williams, N.R., Zarate, C.A., Malievskaia, E. (2022) New England Journal of Medicine , 387(18) , 1637-1648
Zusammenfassung
Phase 2b dose-ranging trial (COMP360) in 233 participants with treatment-resistant depression. The 25 mg psilocybin group showed significantly greater reduction in MADRS depression score at week 3 compared to the 1 mg control group.